Earnings ·
Reports Q3 net loss of $26.5M; cash balance stands at $503.5 million
BRVEBraveheart Bio, Inc.
Braveheart Bio reported a net loss of $26.5 million, or $0.51 per share, for the third quarter ended September 30, 2026, compared to a net loss of $59.1 million in the prior-year period. Research and development expenses increased to $17.5 million from less than $0.1 million, driven by clinical costs for the LIONHEART-HCM trial and a $1.0 million licensing milestone. General and administrative expenses rose to $12.6 million due to personnel and public company costs. The company ended the quarter with $503.5 million in cash, cash equivalents, and investments, providing a runway into 2029. Clinical updates include LIONHEART-HCM enrolling patients with an interim analysis expected in late 2027, while NOBLEHEART-HCM and TRUEHEART-HCM are on track to initiate in the first half of 2027. Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy.